Regulus Therapeutics Inc

NASDAQ RGLS

Data sourced from

and

Daily

Download Data

Regulus Therapeutics Inc Price to Earnings Ratio (P/E) on June 03, 2024: -20.63

Regulus Therapeutics Inc Price to Earnings Ratio (P/E) is -20.63 on June 03, 2024, a -2,458.32% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Regulus Therapeutics Inc 52-week high Price to Earnings Ratio (P/E) is -0.77 on June 21, 2023, which is 96.26% above the current Price to Earnings Ratio (P/E).
Regulus Therapeutics Inc 52-week low Price to Earnings Ratio (P/E) is -895.45 on August 08, 2023, which is -4,240.46% below the current Price to Earnings Ratio (P/E).
Regulus Therapeutics Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -7.78.

NASDAQ: RGLS

Regulus Therapeutics Inc

CEO	Mr. Joseph P. Hagan M.B.A.
IPO Date	Oct. 4, 2012
Location	United States
Headquarters	4224 Campus Point Court, San Diego, CA, United States, 92121
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Key trends